Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999691828> ?p ?o ?g. }
- W2999691828 endingPage "223" @default.
- W2999691828 startingPage "223" @default.
- W2999691828 abstract "Until recently, distant metastatic melanoma was considered refractory to systemic therapy. A better understanding of the interactions between tumors and the immune system and the mechanisms of regulation of T-cells led to the development of immune checkpoint inhibitors. This review summarizes the current novel data on the treatment of metastatic melanoma with anti-programmed cell death protein 1 (PD-1) antibodies and anti-PD-1-based combination regimens, including clinical trials presented at major conference meetings. Immune checkpoint inhibitors, in particular anti-PD-1 antibodies such as pembrolizumab and nivolumab and the combination of nivolumab with the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody ipilimumab can achieve long-term survival for patients with metastatic melanoma. The anti-PD-1 antibodies nivolumab and pembrolizumab were also approved for adjuvant treatment of patients with resected metastatic melanoma. Anti-PD-1 antibodies appear to be well tolerated, and toxicity is manageable. Nivolumab combined with ipilimumab achieves a 5 year survival rate of more than 50% but at a cost of high toxicity. Ongoing clinical trials investigate novel immunotherapy combinations and strategies (e.g., Talimogene laherparepvec (T-VEC), Bempegaldesleukin (BEMPEG), incorporation or sequencing of targeted therapy, incorporation or sequencing of radiotherapy), and focus on poor prognosis groups (e.g., high tumor burden/LDH levels, anti-PD-1 refractory melanoma, and brain metastases)." @default.
- W2999691828 created "2020-01-23" @default.
- W2999691828 creator A5029717763 @default.
- W2999691828 creator A5037516725 @default.
- W2999691828 creator A5077524499 @default.
- W2999691828 creator A5088740883 @default.
- W2999691828 date "2020-01-14" @default.
- W2999691828 modified "2023-10-10" @default.
- W2999691828 title "Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update" @default.
- W2999691828 cites W1968221752 @default.
- W2999691828 cites W1970051943 @default.
- W2999691828 cites W1989121777 @default.
- W2999691828 cites W1990675339 @default.
- W2999691828 cites W2032166347 @default.
- W2999691828 cites W2032211985 @default.
- W2999691828 cites W2043115278 @default.
- W2999691828 cites W2049620463 @default.
- W2999691828 cites W2053520756 @default.
- W2999691828 cites W2060070314 @default.
- W2999691828 cites W2070825440 @default.
- W2999691828 cites W2077517114 @default.
- W2999691828 cites W2097198003 @default.
- W2999691828 cites W2103220202 @default.
- W2999691828 cites W2109274792 @default.
- W2999691828 cites W2112601576 @default.
- W2999691828 cites W2118982164 @default.
- W2999691828 cites W2128035403 @default.
- W2999691828 cites W2159311956 @default.
- W2999691828 cites W2160766792 @default.
- W2999691828 cites W2161890731 @default.
- W2999691828 cites W2166662937 @default.
- W2999691828 cites W2405445310 @default.
- W2999691828 cites W2461921426 @default.
- W2999691828 cites W2499347045 @default.
- W2999691828 cites W2519469881 @default.
- W2999691828 cites W2529373149 @default.
- W2999691828 cites W2553340100 @default.
- W2999691828 cites W2560367415 @default.
- W2999691828 cites W2564318420 @default.
- W2999691828 cites W2572174216 @default.
- W2999691828 cites W2623137661 @default.
- W2999691828 cites W2650204451 @default.
- W2999691828 cites W2727010309 @default.
- W2999691828 cites W2735117693 @default.
- W2999691828 cites W2750781282 @default.
- W2999691828 cites W2752227448 @default.
- W2999691828 cites W2753432434 @default.
- W2999691828 cites W2762347490 @default.
- W2999691828 cites W2763933536 @default.
- W2999691828 cites W2777859145 @default.
- W2999691828 cites W2784063247 @default.
- W2999691828 cites W2786816161 @default.
- W2999691828 cites W2787399901 @default.
- W2999691828 cites W2794627893 @default.
- W2999691828 cites W2797309423 @default.
- W2999691828 cites W2888298425 @default.
- W2999691828 cites W2888349826 @default.
- W2999691828 cites W2889967774 @default.
- W2999691828 cites W2891250023 @default.
- W2999691828 cites W2891790933 @default.
- W2999691828 cites W2894313087 @default.
- W2999691828 cites W2896600825 @default.
- W2999691828 cites W2898313077 @default.
- W2999691828 cites W2902749870 @default.
- W2999691828 cites W2913383852 @default.
- W2999691828 cites W2913685761 @default.
- W2999691828 cites W2922887258 @default.
- W2999691828 cites W2925460615 @default.
- W2999691828 cites W2935725734 @default.
- W2999691828 cites W2943218134 @default.
- W2999691828 cites W2946844252 @default.
- W2999691828 cites W2946881072 @default.
- W2999691828 cites W2947850910 @default.
- W2999691828 cites W2947903267 @default.
- W2999691828 cites W2948155539 @default.
- W2999691828 cites W2948740360 @default.
- W2999691828 cites W2948884915 @default.
- W2999691828 cites W2949375297 @default.
- W2999691828 cites W2950568943 @default.
- W2999691828 cites W2979188159 @default.
- W2999691828 cites W3043703771 @default.
- W2999691828 doi "https://doi.org/10.3390/jcm9010223" @default.
- W2999691828 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7019511" @default.
- W2999691828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31947592" @default.
- W2999691828 hasPublicationYear "2020" @default.
- W2999691828 type Work @default.
- W2999691828 sameAs 2999691828 @default.
- W2999691828 citedByCount "88" @default.
- W2999691828 countsByYear W29996918282020 @default.
- W2999691828 countsByYear W29996918282021 @default.
- W2999691828 countsByYear W29996918282022 @default.
- W2999691828 countsByYear W29996918282023 @default.
- W2999691828 crossrefType "journal-article" @default.
- W2999691828 hasAuthorship W2999691828A5029717763 @default.
- W2999691828 hasAuthorship W2999691828A5037516725 @default.
- W2999691828 hasAuthorship W2999691828A5077524499 @default.
- W2999691828 hasAuthorship W2999691828A5088740883 @default.
- W2999691828 hasBestOaLocation W29996918281 @default.